MCID: CRV038
MIFTS: 60

Cervical Squamous Cell Carcinoma malady

Categories: Reproductive diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Cervical Squamous Cell Carcinoma

About this section
Sources:
11Disease Ontology, 13DISEASES, 31ICD10 via Orphanet, 35LifeMap Discovery®, 45NCIt, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS
See all MalaCards sources

Aliases & Descriptions for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma 35 11 54 50 13 68
Squamous Cell Carcinoma of the Cervix Uteri 11 54
 
Squamous Cell Carcinoma of Cervix 11

Classifications:



External Ids:

Disease Ontology11 DOID:3744
NCIt45 C4028
SNOMED-CT62 254886006
Orphanet54 ORPHA213767
ICD10 via Orphanet31 C53.0, C53.1, C53.8

Summaries for Cervical Squamous Cell Carcinoma

About this section
Disease Ontology:11 A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary: Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to microinvasive cervical squamous cell carcinoma and cervical intraepithelial neoplasia. An important gene associated with Cervical Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways are RHO GTPases activate IQGAPs and TP53 Network. Affiliated tissues include uterus, cervix and lymph node, and related mouse phenotypes are Decreased viability and pigmentation.

Related Diseases for Cervical Squamous Cell Carcinoma

About this section

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 126)
idRelated DiseaseScoreTop Affiliating Genes
1microinvasive cervical squamous cell carcinoma12.2
2cervical intraepithelial neoplasia11.4
3cervicitis10.9
4squamous cell carcinoma10.9
5clear cell adenofibroma10.3CDKN2A, TP53
6linitis plastica10.3CDH1, TP53
7lacrimal gland adenoid cystic carcinoma10.3CDKN2A, TP53
8aml with myelodysplasia-related features10.3CDKN2A, MKI67, TP63
9spondylarthropathy10.3CDKN2A, MKI67, TP53
10oro-mandibular-limb hypogenesis syndrome10.3CDKN2A, MKI67, TP53
11pericardium leiomyoma10.3CDKN2A, TP53
12wolffian adnexal neoplasm10.3EGFR, MKI67, TP53
13mitochondrial encephalomyopathy10.2CDKN2A, TP53, TP63
14spastic paraplegia 110.2EGFR, MKI67, TP53
15myxedema10.2CDKN2A, EGFR, TP53
16endometrial squamous cell carcinoma10.2CDKN2A, RASSF1, TP53
17allergic contact dermatitis10.2CDKN2A, EGFR, TP53
18sengers syndrome10.2CDH1, CDKN2A, EGFR
19vascular myelopathy10.2CDKN2A, SOX2, TP53
20interstitial lung disease10.2CDKN2A, EGFR, TP53
21maxillary sinus cholesteatoma10.2CDH1, CDKN2A, TP53
22coccidiosis10.2CDKN2A, SERPINB3, TP53
23plasmodium ovale malaria10.2CDKN2A, MKI67, TP53, TP63
24intermediate malignant teratoma10.2CDKN2A, EGFR, SERPINB3
25cervical verrucous carcinoma10.2CDKN2A, TP53, TYMP
26dental caries10.2CDH1, EGFR, TP53
27marginal zone b-cell lymphoma10.2CDKN2A, EGFR, TP53
28fallopian tube adenocarcinoma10.2CDKN2A, RASSF1, TP53
29nasal cavity disease10.2CDH1, EGFR, TP53
30lacrimal gland squamous cell carcinoma10.2CDKN2A, KRT8, TP53
31placental site trophoblastic tumor10.2CDKN2A, TP53, TYMP
32his bundle tachycardia10.2EGFR, MKI67, TP53, TP63
33post-surgical hypoinsulinemia10.2CDKN2A, SOX2, TP53
34estrogen-receptor positive breast cancer10.2CDH1, CDKN2A, EGFR, TP53
35cleft palate cardiac defect ectrodactyly10.2EGFR, RASSF1, TP53
36pyomyositis10.2CDH1, CDKN2A, EGFR, TP53
37connective tissue benign neoplasm10.2CDH1, CDKN2A, EGFR, TP53
38occlusion precerebral artery10.2CDKN2A, EGFR, TP53
39charcot-marie-tooth disease type 2n10.2CDKN2A, KRT8, MKI67
40hepatic flexure cancer10.2CDKN2A, EGFR, MKI67, TP53
41bronchitis10.2CDH1, TP53
42ornithinemia10.2CDH1, CDKN2A, EGFR, TP53
43scirrhous adenocarcinoma10.2CDH1, KRT8, TP63
44pancreatic cancer10.2CDH1, KRT8, TP53
45gastrointestinal stromal tumor10.2CDKN2A, EGFR, MKI67, TP53
46ovarian embryonal carcinoma10.2EGFR, KRT8, TP53
47nasopharyngeal carcinoma10.1CDKN2A, EGFR, TP53
48pancreatic cystadenoma10.1EGFR, SOX2, TP53
49fallopian tube leiomyosarcoma10.1CDH1, CDKN2A, DAPK1, TP53
50immunodeficiency 3710.1CDH1, CDKN2A, RASSF1

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:



Diseases related to cervical squamous cell carcinoma

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00381-A-19.5CDH1, CDKN2A, DAPK1, EGFR, SOX2

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

41 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.2CDKN2A, CTNNB1, EGFR, SOX2, TP53
2MP:00053708.6CDKN2A, CTNNB1, EGFR, KRT8, OSMR, RASSF1
3MP:00053808.4CDH1, CDKN2A, CTNNB1, EGFR, KRT8, SOX2
4MP:00020068.4CDH1, CDKN2A, CTNNB1, EGFR, RASSF1, SOX2
5MP:00107718.3CDH1, CDKN2A, CTNNB1, EGFR, OSMR, SOX2
6MP:00030128.3CDH1, CDKN2A, CTNNB1, EGFR, OSMR, SOX2
7MP:00028738.3CDH1, CTNNB1, EGFR, MKI67, RASSF1, SOX2
8MP:00053818.2CDH1, CDKN2A, CTNNB1, EGFR, KRT8, RASSF1
9MP:00053897.8CDH1, CDKN2A, CTNNB1, EGFR, KRT8, SKP2
10MP:00053797.6CDH1, CDKN2A, CTNNB1, EGFR, OSMR, RASSF1
11MP:00053847.5CDH1, CDKN2A, CTNNB1, DAPK1, EGFR, RASSF1
12MP:00053887.3CDKN2A, CTNNB1, EGFR, SERPINB4, SOX2, TP53
13MP:00053766.9CDH1, CDKN2A, CTNNB1, DAPK1, EGFR, KRT8
14MP:00053876.3CDH1, CDKN2A, CTNNB1, EGFR, KRT8, OSMR

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

About this section

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 515)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EthanolapprovedPhase 4, Phase 1213764-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
2
FluorouracilapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
3
CetuximabapprovedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1752205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
4
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
5
CevimelineapprovedPhase 4, Phase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline [INN]
 
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
6
Fentanylapproved, illicit, investigational, vet_approvedPhase 4, Phase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
7
Gefitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1361184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
8
PetrolatumapprovedPhase 4938009-03-8
Synonyms:
Multi-hydrocarbon
Paraffinum album
Paraffinum flavum
Petrolatum base
Petrolatum, white
 
Petrolatum,amber
Petrolatum,white
Petroleum jelly
Soft paraffin
White petrolatum
White, soft paraffin
Yellow soft paraffin
9Titanium dioxideapprovedPhase 43813463-67-7
10
Morphineapproved, investigationalPhase 4100757-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
11
Docetaxelapproved, investigational, Approved May 1996Phase 4, Phase 2, Phase 3, Phase 1, Early Phase 11967114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
12Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14962
13Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 113086
14AnalgesicsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 111733
15Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15806
16Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 18192
17Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 110729
18AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112054
19Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 123689
20Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15657
21Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Early Phase 118340
22Cholinergic AgentsPhase 4, Phase 33992
23VaccinesPhase 4, Phase 3, Phase 2, Phase 16611
24Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 110150
25Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17361
26ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 16394
27AntibodiesPhase 4, Phase 3, Phase 2, Phase 16394
28Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 111226
29Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 17180
30Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 14827
31Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Early Phase 113403
32Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13689
33Anesthetics, IntravenousPhase 4, Phase 32538
34NarcoticsPhase 4, Phase 3, Phase 23646
35MitomycinsPhase 4, Phase 3, Phase 2240
36Epoetin alfaPhase 4, Phase 3, Phase 2658113427-24-0
37HematinicsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11684
38Anesthetics, GeneralPhase 4, Phase 32934
39Adjuvants, AnesthesiaPhase 4, Phase 31674
40AnestheticsPhase 4, Phase 3, Phase 29596
41Analgesics, OpioidPhase 4, Phase 3, Phase 23238
42Anti-Allergic AgentsPhase 4, Phase 21522
43mometasone furoatePhase 417883919-23-7
44arginineNutraceuticalPhase 4, Phase 2, Phase 1425
45Omega 3 Fatty AcidNutraceuticalPhase 4, Phase 2, Phase 11018
46
Irinotecanapproved, investigationalPhase 3, Phase 2, Phase 1112397682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
47
Capecitabineapproved, investigationalPhase 2, Phase 3, Phase 11342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
48
CitalopramapprovedPhase 351259729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
49TegafurapprovedPhase 3, Phase 29617902-23-7
50
Cyclophosphamideapproved, investigationalPhase 3, Phase 2, Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide

Interventional clinical trials:

(show top 50)    (show all 1588)
idNameStatusNCT IDPhase
1Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)Unknown statusNCT01553032Phase 4
2A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous CarcinomaUnknown statusNCT00642239Phase 4
3Epoetin Beta in Treating Anemia in Patients With Cervical CancerCompletedNCT00046969Phase 4
4Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced XerostomiaCompletedNCT00466388Phase 4
5Post-marketing Surveillance Study of Docetaxel-Based ChemotherapyCompletedNCT02972216Phase 4
6Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx CarcinomaCompletedNCT00772681Phase 4
7Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer PatientsCompletedNCT02622880Phase 4
8A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer PatientsCompletedNCT01283906Phase 4
9Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and NeckRecruitingNCT02015650Phase 4
10Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' PatientsRecruitingNCT02495064Phase 4
11Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional GastrostomyRecruitingNCT02869321Phase 4
12An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and NeckActive, not recruitingNCT00684385Phase 4
13Stereotactic Body Radiotherapy for Head and Neck TumorsActive, not recruitingNCT01344356Phase 4
14Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant RecipientsActive, not recruitingNCT02624349Phase 4
15HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal LesionsNot yet recruitingNCT03051516Phase 4
16Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck CancerUnknown statusNCT00002659Phase 3
17S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck CancerUnknown statusNCT00336947Phase 3
18Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.Unknown statusNCT01124409Phase 3
19Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer TreatmentUnknown statusNCT00935675Phase 3
20Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth CancerUnknown statusNCT00002747Phase 3
21Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving MethotrexateUnknown statusNCT00041613Phase 3
22Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy AloneUnknown statusNCT00041626Phase 3
23Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or OropharynxUnknown statusNCT00002702Phase 3
24Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or HypopharynxUnknown statusNCT00003627Phase 3
25Topical Imiquimod for Bowen's Disease of the Head and NeckUnknown statusNCT00384124Phase 2, Phase 3
26Oral Cancer Adjuvant Therapy (OCAT) TrialUnknown statusNCT00193843Phase 3
27PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck CancerUnknown statusNCT00720070Phase 3
28Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the NasopharynxUnknown statusNCT00003637Phase 3
29Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal CancerUnknown statusNCT01434394Phase 2, Phase 3
30Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced XerostomiaUnknown statusNCT00081029Phase 3
31Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea PolyphenolsUnknown statusNCT01496521Phase 3
32Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After EsophagectomyUnknown statusNCT01402180Phase 2, Phase 3
33Elective or Prophylactic Nodal Irradiation for Esophageal CancerUnknown statusNCT01551589Phase 3
34Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 TrialUnknown statusNCT02319187Phase 3
35Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIALUnknown statusNCT01039298Phase 3
36Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the EsophagusUnknown statusNCT00002884Phase 3
37Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal CancerUnknown statusNCT00509561Phase 2, Phase 3
38Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical CancerCompletedNCT00003945Phase 3
39Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and NeckCompletedNCT00442455Phase 3
40Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese SubjectsCompletedNCT01012258Phase 3
41A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and NeckCompletedNCT01177956Phase 3
42Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT01086826Phase 3
43Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)CompletedNCT00206219Phase 3
44Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical CancerCompletedNCT00803062Phase 3
45Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the CervixCompletedNCT00064077Phase 3
46Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)CompletedNCT00122460Phase 3
47Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT00401323Phase 2, Phase 3
48LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyCompletedNCT01345682Phase 3
49Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00771641Phase 3
50DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCCCompletedNCT00496652Phase 3

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Genetic Tests for Cervical Squamous Cell Carcinoma

About this section

Anatomical Context for Cervical Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Cervical Squamous Cell Carcinoma:

36
Uterus, Cervix, Lymph node, T cells, Lung, Testes, Placenta

Publications for Cervical Squamous Cell Carcinoma

About this section

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50)    (show all 308)
idTitleAuthorsYear
1
Chondrosarcoma-like metastasis from a poorly differentiated uterine cervical squamous cell carcinoma. A unique morphology and diagnostic pitfall in cytology. (28411397)
2017
2
Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. (28526810)
2017
3
Sulfiredoxin may promote metastasis and invasion of cervical squamous cell carcinoma by epithelial-mesenchymal transition. (28351308)
2017
4
Integrative genomic and network analysis identified novel genes associated with the development of advanced cervical squamous cell carcinoma. (27641506)
2016
5
Biventricular metastatic invasion from cervical squamous cell carcinoma. (27371746)
2016
6
Prognostic Significance of Cytokeratin 19 and Squamous Cell Cancer Antigen in Histologically Negative Sentinel Lymph Nodes of Cervical Squamous Cell Carcinoma. (27654256)
2016
7
DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. (26992219)
2016
8
The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy. (27400321)
2016
9
TRPV6 is a prognostic marker in early-stage cervical squamous cell carcinoma. (27747588)
2016
10
5-Hydroxymethylcytosine expression is associated with poor survival in cervical squamous cell carcinoma. (26851753)
2016
11
The Value of Diffusion-Weighted Imaging in Predicting the Prognosis of Stage IB-IIA Cervical Squamous Cell Carcinoma After Radical Hysterectomy. (26807567)
2016
12
Functional variant of the P2X7 receptor gene is associated with human papillomavirus-16 positive cervical squamous cell carcinoma. (27779103)
2016
13
UHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma CaSki cells. (27431502)
2016
14
A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass. (27695343)
2016
15
ITPR3 gene haplotype is associated with cervical squamous cell carcinoma risk in Taiwanese women. (28036301)
2016
16
Expression of HIF-2I+ and VEGF in Cervical Squamous Cell Carcinoma and Its Clinical Significance. (27413748)
2016
17
Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. (27351213)
2016
18
Role of difucosylated Lewis Y antigen in outcome of locally advanced cervical squamous cell carcinoma treated with cisplatin regimen. (27197582)
2016
19
High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma. (27941992)
2016
20
Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage II cervical squamous cell carcinoma: A retrospective cohort study. (27131759)
2016
21
A comprehensive expression analysis of the MIA gene family in malignancies: MIA gene family members are novel, useful markers of esophageal, lung, and cervical squamous cell carcinoma. (27145272)
2016
22
Functional significance of transgelin-2 in uterine cervical squamous cell carcinoma. (26891454)
2016
23
Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy. (27087737)
2016
24
Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. (27895779)
2016
25
Involvement of myeloperoxidase gene polymorphism 463G>A in development of cervical squamous cell carcinoma. (27197583)
2016
26
MRI in the synchronic chemoradiotherapy of cervical squamous cell carcinoma. (27352568)
2016
27
Vasculogenic mimicry and hypoxia-inducible factor-1I+ expression in cervical squamous cell carcinoma. (26985936)
2016
28
Expression of E-, P- and N-Cadherin and Its Clinical Significance in Cervical Squamous Cell Carcinoma and Precancerous Lesions. (27223886)
2016
29
I9Np63I+ attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma. (26864590)
2016
30
Scalp Metastasis as a Presenting Symptom of Cervical Squamous Cell Carcinoma. (27105328)
2016
31
Increased expression of long non-coding RNA XIST predicts favorable prognosis of cervical squamous cell carcinoma subsequent to definitive chemoradiation therapy. (27899965)
2016
32
A rare case of HPV-negative cervical squamous cell carcinoma. (25675193)
2015
33
Astrocyte elevated gene-1 promotes progression of cervical squamous cell carcinoma by inducing epithelial-mesenchymal transition via Wnt signaling. (25695541)
2015
34
The landscape of alternative splicing in cervical squamous cell carcinoma. (25565867)
2015
35
Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma. (26271794)
2015
36
ALEX1 may be a novel biomarker for human cervical squamous cell carcinoma. (26464700)
2015
37
Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications. (26209091)
2015
38
Expression and significance of LRIG3 in human cervical squamous cell carcinoma. (26390694)
2015
39
Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma]. (26978018)
2015
40
Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy. (25773678)
2015
41
Detection, genotyping and quantitation of multiple hpv infections in south African women with cervical squamous cell carcinoma. (26037775)
2015
42
Putative stem cell markers in cervical squamous cell carcinoma are correlated with poor clinical outcome. (26499463)
2015
43
Prognostic significance of TRAIL signalling molecules in cervical squamous cell carcinoma. (26254281)
2015
44
Immunohistochemical Expression and Prognostic Significance of CD97 and its Ligand DAF in Human Cervical Squamous Cell Carcinoma. (26107567)
2015
45
Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta. (25434636)
2015
46
A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study. (26252302)
2015
47
Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/I^-catenin signaling. (26427870)
2015
48
Transcriptome profiling of the cancer and adjacent nontumor tissues from cervical squamous cell carcinoma patients by RNA sequencing. (25586346)
2015
49
The prognostic value of squamous cell carcinoma antigen for predicting tumor recurrence in cervical squamous cell carcinoma patients. (26430661)
2015
50
An insertion/deletion polymorphism at miRNA-122 binding site in the IL1A is associated with a reduced risk of cervical squamous cell carcinoma. (25955681)
2015

Variations for Cervical Squamous Cell Carcinoma

About this section

Cosmic variations for Cervical Squamous Cell Carcinoma:

8 (show top 50)    (show all 53)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM715FGFR3cervix,NS,carcinoma,squamous cell carcinomac.746C>Gp.S249C12
2COSM518KRAScervix,NS,carcinoma,squamous cell carcinomac.34G>Cp.G12R12
3COSM43896TP53cervix,NS,carcinoma,squamous cell carcinomac.818G>Cp.R273P12
4COSM580NRAScervix,NS,carcinoma,squamous cell carcinomac.181C>Ap.Q61K12
5COSM49175FGFR2cervix,NS,carcinoma,squamous cell carcinomac.1976A>Tp.K659M12
6COSM499HRAScervix,NS,carcinoma,squamous cell carcinomac.182A>Gp.Q61R12
7COSM763PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1633G>Ap.E545K12
8COSM12459PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1637A>Gp.Q546R12
9COSM483HRAScervix,NS,carcinoma,squamous cell carcinomac.35G>Tp.G12V12
10COSM10725TP53cervix,NS,carcinoma,squamous cell carcinomac.701A>Gp.Y234C12
11COSM13646CDKN2Acervix,NS,carcinoma,squamous cell carcinomac.392G>Tp.R131L12
12COSM773PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.3129G>Tp.M1043I12
13COSM10648TP53cervix,NS,carcinoma,squamous cell carcinomac.524G>Ap.R175H12
14COSM44029TP53cervix,NS,carcinoma,squamous cell carcinomac.550G>Ap.D184N12
15COSM480HRAScervix,NS,carcinoma,squamous cell carcinomac.34G>Ap.G12S12
16COSM45507TP53cervix,NS,carcinoma,squamous cell carcinomac.806G>Cp.S269T12
17COSM760PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1624G>Ap.E542K12
18COSM10889TP53cervix,NS,carcinoma,squamous cell carcinomac.536A>Gp.H179R12
19COSM29464STK11cervix,NS,carcinoma,squamous cell carcinomac.169G>Tp.E57*12
20COSM497HRAScervix,NS,carcinoma,squamous cell carcinomac.181C>Gp.Q61E12
21COSM775PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.3140A>Gp.H1047R12
22COSM10705TP53cervix,NS,carcinoma,squamous cell carcinomac.586C>Tp.R196*12
23COSM10659TP53cervix,NS,carcinoma,squamous cell carcinomac.817C>Tp.R273C12
24COSM11356TP53cervix,NS,carcinoma,squamous cell carcinomac.726C>Gp.C242W12
25COSM12458PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1634A>Cp.E545A12
26COSM46185TP53cervix,NS,carcinoma,squamous cell carcinomac.775G>Cp.D259H12
27COSM17442PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1624G>Cp.E542Q12
28COSM5731CTNNB1cervix,NS,carcinoma,squamous cell carcinomac.113G>Cp.G38A12
29COSM29465STK11cervix,NS,carcinoma,squamous cell carcinomac.320A>Gp.H107R12
30COSM45259TP53cervix,NS,carcinoma,squamous cell carcinomac.301A>Tp.K101*12
31COSM5662CTNNB1cervix,NS,carcinoma,squamous cell carcinomac.110C>Tp.S37F12
32COSM43662TP53cervix,NS,carcinoma,squamous cell carcinomac.868C>Ap.R290S12
33COSM766PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1636C>Ap.Q546K12
34COSM10749TP53cervix,NS,carcinoma,squamous cell carcinomac.830G>Tp.C277F12
35COSM1168056PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.3145G>Tp.G1049C12
36COSM552KRAScervix,NS,carcinoma,squamous cell carcinomac.182A>Gp.Q61R12
37COSM3734673STK11cervix,NS,carcinoma,squamous cell carcinomac.597G>Cp.E199D12
38COSM12469CDKN2Acervix,NS,carcinoma,squamous cell carcinomac.244G>Ap.V82M12
39COSM5730CTNNB1cervix,NS,carcinoma,squamous cell carcinomac.122C>Ap.T41N12
40COSM11483TP53cervix,NS,carcinoma,squamous cell carcinomac.848G>Ap.R283H12
41COSM551KRAScervix,NS,carcinoma,squamous cell carcinomac.182A>Cp.Q61P12
42COSM555KRAScervix,NS,carcinoma,squamous cell carcinomac.183A>Tp.Q61H12
43COSM10662TP53cervix,NS,carcinoma,squamous cell carcinomac.743G>Ap.R248Q12
44COSM43624TP53cervix,NS,carcinoma,squamous cell carcinomac.875A>Gp.K292R12
45COSM43660TP53cervix,NS,carcinoma,squamous cell carcinomac.719G>Tp.S240I12
46COSM517KRAScervix,NS,carcinoma,squamous cell carcinomac.34G>Ap.G12S12
47COSM13778CDKN2Acervix,NS,carcinoma,squamous cell carcinomac.376G>Ap.V126I12
48COSM120958NFE2L2cervix,NS,carcinoma,squamous cell carcinomac.235G>Cp.E79Q12
49COSM521KRAScervix,NS,carcinoma,squamous cell carcinomac.35G>Ap.G12D12
50COSM5089PTENcervix,NS,carcinoma,squamous cell carcinomac.517C>Tp.R173C12

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

6 (show all 38)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
11914445115100000GainPDCD6Cervical squamous cell carcinoma
21914665118500000GainPOLSCervical squamous cell carcinoma
31914675118500000GainSDHACervical squamous cell carcinoma
41914685118500000GainSRD5A1Cervical squamous cell carcinoma
51916245142400000GainRPL37Cervical squamous cell carcinoma
61916255142400000GainSKP2Cervical squamous cell carcinoma
71916275142400000GainSLC1A3Cervical squamous cell carcinoma
8191642514400000GainIRX2Cervical squamous cell carcinoma
9191643514400000GainNDUFS6Cervical squamous cell carcinoma
10191644514400000GainTERTCervical squamous cell carcinoma
11191646514400000GainTRIP13Cervical squamous cell carcinoma
12191726518200000GainIRX4Cervical squamous cell carcinoma
1319545151510000018500000GainANKHCervical squamous cell carcinoma
1419545251510000018500000GainZNF622Cervical squamous cell carcinoma
1519545351510000023300000GainMYO10Cervical squamous cell carcinoma
1619545451510000029300000GainBASP1Cervical squamous cell carcinoma
1719872552930000034400000GainDROSHACervical squamous cell carcinoma
1819872652930000034400000GainGOLPH3Cervical squamous cell carcinoma
1919872752930000034400000GainMTMR12Cervical squamous cell carcinoma
2019872852930000034400000GainSUB1Cervical squamous cell carcinoma
2119907653440000038500000GainDNAJA5Cervical squamous cell carcinoma
2219907853440000038500000GainLMBRD2Cervical squamous cell carcinoma
2319907953440000038500000GainNIPBLCervical squamous cell carcinoma
2419908053440000038500000GainRAD1Cervical squamous cell carcinoma
2519908253440000038500000GainTARSCervical squamous cell carcinoma
2619908353440000038500000GainWDR70Cervical squamous cell carcinoma
2719938453850000042400000GainNUP155Cervical squamous cell carcinoma
2819938553850000042400000GainOXCT1Cervical squamous cell carcinoma
2919968454240000045800000GainCCL28Cervical squamous cell carcinoma
3019968554240000045800000GainFBXO4Cervical squamous cell carcinoma
3119968654240000045800000GainPAIP1Cervical squamous cell carcinoma
3219968954240000047700000GainZNF131Cervical squamous cell carcinoma
33199835544000006000000GainKIAA0947Cervical squamous cell carcinoma
342024515820000015100000GainCCT5Cervical squamous cell carcinoma
352024525820000015100000GainDAPCervical squamous cell carcinoma
362024545820000015100000GainMARCH-VICervical squamous cell carcinoma
372024625820000023300000GainZFYVE16Cervical squamous cell carcinoma
382024645820000045800000GainOSRFCervical squamous cell carcinoma

Expression for genes affiliated with Cervical Squamous Cell Carcinoma

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 33)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1CRNNcornulinUterus-5.620.000
2KRT1keratin 1, type IIUterus-5.320.000
3UPK1Auroplakin 1AUterus-4.790.000
4MALmal, T-cell differentiation proteinUterus-4.730.000
5KRT4keratin 4, type IIUterus-4.450.000
6SPRR3small proline-rich protein 3Uterus-4.430.000
7DSG1desmoglein 1Uterus-4.270.000
8CDKN2Acyclin-dependent kinase inhibitor 2AUterus+4.210.000
9CRISP3cysteine-rich secretory protein 3Uterus-4.130.000
10CRCT1cysteine-rich C-terminal 1Uterus-3.920.000
11SPINK5serine peptidase inhibitor, Kazal type 5Uterus-3.670.000
12SLURP1secreted LY6/PLAUR domain containing 1Uterus-3.540.000
13APOC1apolipoprotein C-IUterus+3.530.000
14HOPXHOP homeoboxUterus-3.510.000
15EDN3endothelin 3Uterus-3.480.000
16FANCIFanconi anemia, complementation group IUterus+3.420.000
17SYNGR3synaptogyrin 3Uterus+3.410.000
18CRYABcrystallin, alpha BUterus-3.390.000
19KRT13keratin 13, type IUterus-3.350.004
20MCM5minichromosome maintenance complex component 5Uterus+3.310.000
21ALOX12arachidonate 12-lipoxygenaseUterus-3.260.000
22PPP1R3Cprotein phosphatase 1, regulatory subunit 3CUterus-3.230.000
23SCELsciellinUterus-3.190.000
24NTSneurotensinUterus+3.190.006
25NUSAP1nucleolar and spindle associated protein 1Uterus+3.170.000
26IVLinvolucrinUterus-3.140.000
27IL1R2interleukin 1 receptor, type IIUterus-3.140.000
28CFDcomplement factor D (adipsin)Uterus-3.130.000
29SOSTDC1sclerostin domain containing 1Uterus-3.080.000
30ESR1estrogen receptor 1Uterus-3.060.000
31PAMR1peptidase domain containing associated with muscle regeneration 1Uterus-3.060.000
32ENDOUendonuclease, polyU-specificUterus-3.040.000
33HOXC6homeobox C6Uterus+3.010.000

Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.

Pathways for genes affiliated with Cervical Squamous Cell Carcinoma

About this section

Pathways related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
idSuper pathwaysScoreTop Affiliating Genes
19.7CDH1, CTNNB1
2
Show member pathways
9.6CDKN2A, TP53, TP63
39.5CTNNB1, KRT8, MKI67
49.5CDKN2A, EGFR, TP53
5
Show member pathways
9.3RASSF1, SKP2, TP53
69.3CDH1, CTNNB1, TP53
79.3CDH1, CTNNB1, EGFR
89.3CDH1, CTNNB1, EGFR
9
Show member pathways
9.3CDH1, CTNNB1, EGFR
109.2CTNNB1, EGFR, TP53
11
Show member pathways
9.1CDH1, CDKN2A, SKP2, TP53
129.0CDKN2A, CTNNB1, EGFR, TP53
139.0CDKN2A, EGFR, RASSF1, TP53, TP63
148.9CDKN2A, CTNNB1, HLA-DRB1, TP53
15
Show member pathways
8.9CDH1, CTNNB1, EGFR, TP53
168.9CDH1, CTNNB1, EGFR, TP53
178.9CDH1, CTNNB1, EGFR, TP53
188.8CDH1, CTNNB1, RASSF1, SOX2
198.8CDKN2A, MKI67, SKP2, TP53, TP63
20
Show member pathways
8.5CDH1, CDKN2A, CTNNB1, EGFR, RASSF1, TP53
21
Show member pathways
8.5CDH1, CDKN2A, DAPK1, EGFR, RASSF1, TP53
227.7CDH1, CDKN2A, CTNNB1, DAPK1, EGFR, RASSF1

GO Terms for genes affiliated with Cervical Squamous Cell Carcinoma

About this section

Cellular components related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1apical junction complexGO:004329610.5CDH1, CTNNB1
2catenin complexGO:001634210.5CDH1, CTNNB1
3flotillin complexGO:00166009.7CDH1, CTNNB1
4cytoplasmGO:00057375.1CDH1, CDKN2A, CTNNB1, DAPK1, DNAJC9, EGFR

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.5TP53, TP63
2mitotic G1 DNA damage checkpointGO:003157110.5TP53, TP63
3replicative senescenceGO:009039910.4CDKN2A, TP53
4cellular response to indole-3-methanolGO:007168110.4CDH1, CTNNB1
5entry of bacterium into host cellGO:003563510.4CDH1, CTNNB1
6regulation of myelinationGO:003164110.3CTNNB1, TYMP
7Ras protein signal transductionGO:000726510.3CDKN2A, RASSF1, TP53
8regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:004328110.1SOX2, TP63
9protein tetramerizationGO:00512629.9HLA-DRB1, TP53, TP63
10cell cycle arrestGO:00070509.8CDKN2A, RASSF1, SOX2, TP53
11single organismal cell-cell adhesionGO:00163379.3CDH1, CTNNB1, EGFR
12cell proliferationGO:00082839.2CTNNB1, EGFR, MKI67, SKP2, TP53
13regulation of apoptotic processGO:00429819.1CTNNB1, DAPK1, SKP2, TP53, TP63
14positive regulation of transcription, DNA-templatedGO:00458938.5CDH1, CDKN2A, CTNNB1, EGFR, SOX2, TP53

Molecular functions related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein phosphatase bindingGO:00199039.8CTNNB1, EGFR, TP53
2protease bindingGO:00020209.7SERPINB3, SERPINB4, TP53
3transcription regulatory region DNA bindingGO:00442128.7CTNNB1, SOX2, TP53, TP63

Sources for Cervical Squamous Cell Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet